ALP Bio
Last verified 2026-05-06. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.1Mattributed |
|---|---|
| Latest round | pre-seed, $2.1M, 2026-04-30attributed |
| Founded | 2025 |
| Headquarters | Schlieren, CH |
| Industry | bio |
| Stage | pre-seed |
| Website | alp.bio |
Alp Bio runs immunogenicity assessment for therapeutic antibodies using tonsil-organoid technology plus protein AI. It serves biopharma teams developing monoclonals. Differentiator: human ex-vivo immune readouts fused with ML to predict anti-drug antibody formation early.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-30 | pre-seed | $2.1M | undisclosed |
Detected tech stack
LiteSpeed, PHP 8.3.30, WordPress 6.9.4, Moment.js, Hostinger, HubSpot, WordPress Block Editor, WordPress Site Editor, React, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Pre-seed, $2.1M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $2.1M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | alp.bio, read 2026-05-06 |
| Description | self-reported | alp.bio, read 2026-05-06 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.